Lorient Capital has taken a controlling stake in PeterMD, the New York‑based health‑optimization platform founded in 2014. The private‑equity firm led a majority equity investment, though the price tag remains undisclosed. The deal also placed David Prokupek on PeterMD’s board as executive chair, signalling Lorient’s intent to shape the company’s growth trajectory.

PeterMD offers precision‑medicine tools that blend genetic testing, lifestyle coaching and remote monitoring to personalize care. With Lorient’s backing, the company aims to scale its services beyond regional pilots into a national network, targeting insurers and employer‑sponsored health plans. Expansion could accelerate consolidation in a fragmented digital‑health market where scale remains a competitive edge.

Investors will watch whether the infusion of capital translates into measurable patient enrollment and revenue lift as PeterMD rolls out its platform across multiple states. Early traction could validate Lorient’s strategy of backing niche health‑tech firms poised for broader adoption, while a stalled rollout would raise questions about the scalability of precision‑medicine models.

The partnership arrives as insurers grapple with rising cost pressures and seek data‑driven solutions to improve outcomes. By embedding PeterMD’s analytics into existing benefit designs, Lorient hopes to capture a share of the $10 billion digital‑health spend projected for the next five years, positioning the firm as a key player in the evolving care ecosystem.